Fluconazole and Secnidazole

Phase 3Small molecule

Fluconazole and Secnidazole is one of 4 small molecule programs targeting Vaginal Discharge. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaginal DischargeActive, not recruiting

Vaginal DischargePhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Vaginal Discharge

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lotrimin

1 3

Flagyl

DDePuy Orthopaedics

Phase 3

1 4

Fluconazole and Secnidazole

UUniversidad Nacional de Colombia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaginal Discharge1 trial

Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge

Completed·UUniversidad Nacional de Colombia·Phase 3·NCT02111629·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluconazole and Secnidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluconazole and Secnidazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluconazole and Secnidazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Nacional de Colombia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversidad Nacional de Colombia

Fluconazole and Secnidazole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaginal Discharge1 trial

References

Drug Info

Quick Facts

Related News